SVRA vs ABBV vs AMGN vs JNJ

For growth investors, Amgen Inc.

(AMGN) is the stronger pick with 9. 9% revenue growth year-over-year, versus 4. 3% for Johnson & Johnson (JNJ). Amgen Inc. (AMGN) offers the better valuation at 23. 1x trailing P/E (14. 7x forward), making it the more compelling value choice. Analysts rate Savara Inc. (SVRA) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Amgen Inc.

(AMGN) is the cheapest at 23. 1x versus AbbVie Inc. at 85. 5x. On forward P/E, AbbVie Inc. is actually cheaper at 14. 3x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Amgen Inc. wins at 5. 01x versus Johnson & Johnson's 34. 17x.

Over the past 5 years, Savara Inc.

(SVRA) delivered a total return of +216. 6%, compared to +46. 1% for Johnson & Johnson (JNJ). Over 10 years, the gap is even starker: ABBV returned +295. 5% versus SVRA's -41. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Johnson & Johnson (JNJ) is the lower-risk stock at 0.

06β versus Savara Inc. 's 1. 23β — meaning SVRA is approximately 2057% more volatile than JNJ relative to the S&P 500. On balance sheet safety, Savara Inc. (SVRA) carries a lower debt/equity ratio of 16% versus 6% for Amgen Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Amgen Inc.

(AMGN) is pulling ahead at 9. 9% versus 4. 3% for Johnson & Johnson (JNJ). On earnings-per-share growth, the picture is similar: Amgen Inc. grew EPS 88. 2% year-over-year, compared to -57. 8% for Johnson & Johnson. Over a 3-year CAGR, AMGN leads at 11. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Amgen Inc.

(AMGN) is the more profitable company, earning 21. 0% net margin versus 0. 0% for Savara Inc. — meaning it keeps 21. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ABBV leads at 32. 8% versus 0. 0% for SVRA. At the gross margin level — before operating expenses — AMGN leads at 70. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Amgen Inc. (AMGN) is the more undervalued stock at a PEG of 5. 01x versus Johnson & Johnson's 34. 17x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, AbbVie Inc. (ABBV) trades at 14. 3x forward P/E versus 19. 2x for Johnson & Johnson — 4. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SVRA: 93. 8% to $10. 00.

In this comparison, ABBV (3.

2% yield), AMGN (2. 9% yield), JNJ (2. 2% yield) pay a dividend. SVRA does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Johnson & Johnson (JNJ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

06), 2. 2% yield, +132. 3% 10Y return). Both have compounded well over 10 years (JNJ: +132. 3%, SVRA: -41. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SVRA is a small-cap quality compounder stock; ABBV is a large-cap income-oriented stock; AMGN is a mid-cap quality compounder stock; JNJ is a large-cap quality compounder stock. ABBV, AMGN, JNJ pay a dividend while SVRA does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.